UCB Publishes Results of Fintepla (fenfluramine) in the P-III Trial for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in JAMA Neurology
Shots:
- The P-III trial evaluates Fintepla (0.7/0.2mg/kg/day) vs PBO in 263 patients aged 2-35yrs. with seizures associated with LGS at 65 sites in the EU, North America & Australia
- The trial met its primary efficacy EPs i.e., reduction in frequency of drop seizures in 0.7mg/kg/day (26.5%) vs 14.2% in 0.2mg/kg/day & 7.6% in PBO. In the 2EPs, ≥50% reduction in drop seizure frequency
- In seizure-type subgroup analyses, Fintepla (0.7mg/kg/day) was effective in reducing the frequency of GTCs in 50% of patients, reduction in frequency (45.7% in 0.7mg/kg/day) in maintenance & titration period; 58.2% in 0.2mg/kg/day & 3.7% in PBO, reduction in tonic or atonic seizure frequency (46.7% in 0.7mg/kg/day vs 6.8% in PBO)
Ref: PRNewswire | Image: UCB
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
